Rheumatoid Arthritis Trial, Recruiting NCT07138729 Sponsor: Luo Yaping Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Rheumatoid Arthritis Trial, Recruiting

NCT07138729
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old
  • You have been diagnosed with rheumatoid arthritis according to the 2010 American College of Rheumatology/European Union for Rheumatology classification criteria
  • You have a high level of disease activity, measured by a clinical scoring system called CDAI or SDAI (confirm with trial site, as the specific score requirement appears incomplete in the available information)

Who may not be able to join:

  • You have another autoimmune disease in addition to rheumatoid arthritis
  • You currently have or have been diagnosed with a tumor or cancer
  • You are pregnant, planning to become pregnant, currently breastfeeding, or plan to have children during the study period; if you are of childbearing age, you would need to use effective contraception throughout the study
  • You currently have an active infection of any kind
  • You have claustrophobia or another mental health condition that may make it difficult to cooperate fully with the research team
  • The trial team has any other reason they feel makes participation unsuitable for you (confirm with trial site)

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Please note that some eligibility details in the original criteria appeared to be incomplete, so we recommend contacting the trial site to confirm the full requirements.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yaping LUO, Peking Union Medical College Hospital

Phone: 86-010-69154716

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Luo Yaping
Registry
ClinicalTrials.gov
Start date
10 May 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The number of affected joints detected by 99mTC-TCR-FAPI SPECT

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov